BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended	9 Months Ended
Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Pro forma of consolidated results of operations
Revenues	$ 1,805,197	$ 1,910,348	$ 5,602,093	$ 5,745,192
Net loss attributable to Valeant Pharmaceuticals International, Inc.	$ (960,328)	$ (113,069)	$ (1,045,224)	$ (543,133)
Basic and diluted loss per share (in dollars per share)	$ (2.88)	$ (0.34)	$ (3.13)	$ (1.63)

Name:	us-gaap_BusinessAcquisitionProFormaInformationAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business Acquisition, Pro Forma Earnings Per Share, Basic and Diluted

+ References

No definition available.

+ Details

Name:	vrx_BusinessAcquisitionProFormaEarningsPerShareBasicandDiluted
Namespace Prefix:	vrx_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration